Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | INSR | P06213 | 3/20 | 0.57 |
| ▸ | TEK | Q02763 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394114 | 1.00 | KDR (0.57) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6394127 | 1.00 | KDR (0.57) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6729957 | 0.86 | IRAK4 (0.56) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6395906 | 0.85 | KDR (0.60) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6397216 | 0.85 | KDR (0.48) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6313522 | 0.82 | KDR (0.51) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6397207 | 0.82 | KDR (0.51) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6313512 | 0.82 | KDR (0.51) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6729217 | 0.81 | KDR (0.50) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6392417 | 0.81 | KDR (0.84) | KDRINSRTEKPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549645-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | claimed |
| WO-2004031184-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| CN-106232595-B | Diaminotriazine compounds as herbicides | 巴斯夫欧洲公司 | 2020-01-14 | — | — | CN | disclosed |
| US-9822105-B2 | Diaminotriazine compounds as herbicides | BASF SE (DE) | 2017-11-21 | — | — | US | disclosed |
| EP-3134400-A1 | DIAMINOTRIAZINE COMPOUNDS AS HERBICIDES | BASF SE (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050954-A1 | Diaminotriazine Compounds as Herbicides | BASF SE (DE) | 2017-02-23 | — | — | US | disclosed |
| WO-2015162169-A1 | DIAMINOTRIAZINE COMPOUNDS AS HERBICIDES | BASF SE (DE) | 2015-10-29 | — | — | WO | disclosed |
| EP-1549645-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004031184-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | KDR 2/4885INSR 358/4885TEK 5/4885 |
| US-20170050954-A1 | Diaminotriazine Compounds as Herbicides | NR4A3, RXRB, CBR3 | KDR 936/4885INSR 835/4885TEK 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.